Key Event: API Impurity and Supply Halt
The company scaled up the synthetic API manufacturing process at its API facility to increase output for the global semaglutide injection market. While the API itself met specifications, testing of the finished drug product revealed one impurity was out of specifications due to degradation during the formulation process. This was identified in validation batches for the new scale-up process. As a result, the company has halted commercial supplies and is undertaking a thorough investigation to determine the root cause and implement necessary process improvements.
Timeline and Impact on Supply
The resolution process involves making adjustments to the API process, producing three new validation batches, sending them to partner OneSource for drug product manufacturing, and completing testing (including sterility tests that take up to three weeks). The entire activity is estimated to take until September 2026. If successful, commercial API supply to OneSource could resume in October 2026, with commercial supply of pens to the market resuming in late October or early November 2026. This results in an expected supply halt of approximately three months (from July to September 2026).
Financial and Inventory Impact
Management indicated that inventory lying with OneSource associated with the impacted batches will likely need to be written down. The exact value was not disclosed as the company is in its silent period ahead of Q1 FY27 results. The event will result in missed sales during the supply halt period, representing a downside to previously discussed financial targets. The company's targeted 20%+ EBITDA margin remains unchanged aside from this specific event.
Regulatory and Safety Implications
There is no impact on the product's existing global regulatory filings (approved or under review). No prior approval from any regulatory agency (e.g., Canadian authorities) is required for the process re-validation. Management confirmed there is no patient safety impact associated with product already supplied to the market, as the impacted batches were never shipped. There is also no impact on the supply of Semaglutide oral tablets, which uses a different API source.
Partner and Market Impact
The company supplies semaglutide injection to its long-term partner, OneSource. The halt affects future supply to all partners, including companies in Canada and India (e.g., Sandoz, Torrent). The company has communicated the issue to all partners. There are no anticipated financial penalties for failure to supply, though some arrangements involving down payments may need renegotiation. Demand continues to outstrip supply globally, and the company remains confident in its target of supplying 6-7 million pens between Q3 and Q4 FY27 (November 2026 to March 2027) assuming successful validation.
Contingency Plans
The company is qualifying an alternate API supplier as a backup; however, this would require a pre-approval supplement submission, making it approximately one year away from being viable. The company remains committed to its long-term partnership with OneSource for fill-finish operations while also building its own captive manufacturing facility, plans for which remain valid but will be delayed by the few months needed to resolve the current API issue.
Additional Clarifications
Management clarified that a separate, unrelated recall of one batch in India was initiated around the same time but has no connection to this scale-up issue. The current problem is related to the process and reaction of the API manufacturing, not raw materials or equipment, and is expected to be resolved through parameter tweaks rather than equipment changes.